|
|
|
|
Medarex to Receive Milestone Payment for the Approval of Ilaris for the Treatment of Cryopyrin-Associated Peri
Other Inflammatory Disease Studies Underway in Systemic Juvenile Idiopathic Arthritis, Some Forms of Gout and Type 2 Diabetes PRINCETON, N.J.--(BUSINESS WIRE)--Jun 30, 2009 - Medarex, Inc.(NASDAQ:MEDX) today announced it will...
|
|
|
Abbott to Pay J&J $1.67B for Patent Violation
A federal jury in Texas has ordered Abbott Laboratories to pay $1.67 billion to Centocor Ortho Biotech Inc., a unit of Johnson & Johnson (JNJ), for violating a patent related to the arthritis treatment Remicade.J&J introduced the...
|
|
|
EULAR 2009: Etanercept Safe, Effective in Young Children With Juvenile Idiopathic Arthritis
_ EULAR 2009: Etanercept Safe, Effective in Young Children With Juvenile Idiopathic Arthritis.
|
|
|
EULAR 2009: Etanercept Safe, Effective in Young Children With Juvenile Idiopathic Arthritis
_ EULAR 2009: Etanercept Safe, Effective in Young Children With Juvenile Idiopathic Arthritis.
|
|
|
3 Studies Confirm The Value Of Etanercept Therapy In Treating Juvenile Idiopathic Arthritis
Three new studies have individually shown the anti-TNF (tumour necrosis factor) therapy etanercept to be effective, with a good safety profile, in children under four years of age with juvenile idiopathic arthritis (JIA), and associated with...
|
|
|
Subclinical Markers Predict Relapse In Juvenile Idiopathic Arthritis Post Methotrexate Withdrawal
Elevated levels of the inflammatory biomarkers Myeloid Related Protein (MRP*) 8/14 predict an increased risk of relapse following withdrawal of methotrexate (MTX) therapy in children with juvenile idiopathic arthritis (JIA) who have achieved...
|
|
|
The Effect of the FDAs Investigation of TNF-alpha Inhibitors on Prescribing Patterns and Reimbursement in P
Based on our 2009 Physician & Payer Forum report entitled TNF-alpha Inhibitors in Pediatric Crohn's Disease and Juvenile Idiopathic Arthritis: How Will Physicians and Payers Balance Effective Treatments and Serious Safety...
|
